Ardelyx (NASDAQ:ARDX) Insider Laura Williams Sells 10,739 Shares

Ardelyx, Inc. (NASDAQ:ARDX) insider Laura Williams sold 10,739 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $41,452.54. Following the transaction, the insider owned 367,456 shares of the company’s stock, valued at $1,418,380.16. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ardelyx Price Performance

Shares of ARDX opened at $3.78 on Wednesday. The firm has a market capitalization of $941.94 million, a price-to-earnings ratio of -17.18 and a beta of 0.70. The firm’s fifty day simple moving average is $4.97 and its 200-day simple moving average is $5.75. Ardelyx, Inc. has a twelve month low of $3.72 and a twelve month high of $8.40. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%.The business’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) EPS. Equities analysts forecast that Ardelyx, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ARDX. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. Piper Sandler decreased their target price on Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, August 17th. LADENBURG THALM/SH SH assumed coverage on Ardelyx in a research note on Tuesday, June 16th. They set a “buy” rating and a $16.00 target price for the company. TD Cowen dropped their price target on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Wedbush reiterated an “outperform” rating and issued a $9.00 price target on shares of Ardelyx in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Ardelyx has a consensus rating of “Moderate Buy” and a consensus target price of $13.90.

More Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Hedge Funds Weigh In On Ardelyx

Several large investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Ardelyx during the second quarter worth about $35,000. SCS Capital Management LLC purchased a new stake in shares of Ardelyx in the 2nd quarter valued at about $52,000. ADAR1 Capital Management LLC acquired a new stake in shares of Ardelyx in the 2nd quarter valued at about $56,000. State of Wyoming acquired a new stake in shares of Ardelyx in the 2nd quarter valued at about $61,000. Finally, PVG Asset Management Corp acquired a new stake in shares of Ardelyx in the 1st quarter valued at about $65,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio?renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.